Session Description
Cystic fibrosis related diabetes (CFRD) affects up to a quarter of adolescents and half of adults with cystic fibrosis (CF) and can add significant challenges to health and longevity. Despite recent advances in nutritional status and pulmonary function in the setting of highly effective CFTR modulator therapy, CFRD remains a challenging health issue that can add substantial treatment burden to this patient population. This session will (1) review important background on CFRD, including how it is different than type 1 and type 2 diabetes; (2) explore challenges in the screening and diagnosis of CFRD, including controversies over when to start treatment; and (3) discuss advances in management strategies, including emerging diabetes technologies and non-insulin therapies.